Abstract:Background: Contrast-Associated Acute Kidney Injury (CA-AKI) is a serious complication associated with percutaneous coronary intervention (PCI). Patients with chronic kidney disease (CKD) have an elevated risk for developing this complication. Although CA-AKI prophylactic measures are available, the supporting literature is variable and inconsistent for periprocedural hydration and N-acetylcysteine (NAC), but is stronger for contrast minimization. Methods: We assessed the prevalence and variability of CA-AKI prophylaxis among CKD patients undergoing PCI between October 2007 and September 2015 in any cardiac catheterization laboratory in the VA Healthcare System. Prophylaxis included periprocedural hydration with normal saline or sodium bicarbonate, NAC, and contrast minimization (contrast volume to glomerular filtration rate ratio ≤ 3). Multivariable hierarchical logistic regression models quantified site-specific prophylaxis variability. As secondary analyses, we also assessed CA-AKI prophylaxis measures in all PCI patients regardless of kidney function, periprocedural hydration in patients with comorbid CHF, and temporal trends in CA-AKI prophylaxis. Results: From 2007 to 2015, 15,729 patients with CKD underwent PCI. 6928 (44.0%) received periprocedural hydration (practice-level median rate 45.3%, interquartile range (IQR) 35.5-56.7), 5107 (32.5%) received NAC (practice-level median rate 28.3%, IQR 22.8-36.9), and 4656 (36.0%) received contrast minimization (practice-level median rate 34.5, IQR 22.6-53.9). After adjustment for patient characteristics, there was significant site variability with a median odds ratio (MOR) of 1.80 (CI 1.56-2.08) for periprocedural hydration, 1.95 (CI 1.66-2.29) for periprocedural hydration or NAC, and 2.68 (CI 2.23-3.15) for contrast minimization. These trends were similar among all patients (with and without CKD) undergoing PCI. Among patients with comorbid CHF (n = 5893), 2629 (44.6%) received periprocedural hydration, and overall had less variability in hydration (MOR of 1.56 (CI 1.38-1.76)) compared to patients without comorbid CHF (1.89 (CI 1.65-2.18)). Temporal trend analysis showed a significant and clinically relevant decrease in NAC use (64.1% of cases in 2008 (N = 1059), 6.2% of cases in 2015 (N = 128, p = < 0.0001)) and no significant change in contrast-minimization (p = 0.3907). Conclusions: Among patients with CKD undergoing PCI, there was low utilization and significant site-level variability for periprocedural hydration and NAC independent of patient-specific risk. This low utilization and high variability, however, was also present for contrast minimization, a well-established measure. These findings suggest that a standardized approach to CA-AKI prophylaxis, along with continued development of the evidence base, is needed.

Acute Kidney Injury and Patients Undergoing Both Right and Left Heart Catheterization with Coronary Angiography Versus Right Heart Catheterization Only

Association of the Classification and Severity of Heart Failure with the Incidence of Contrast-Induced Acute Kidney Injury

Acute Kidney Injury in Patients with Nephrotic Syndrome Undergoing Contrast-Enhanced CT for Suspected Venous Thromboembolism: a Propensity Score-Matched Retrospective Cohort Study

Is intravenous iodinated contrast medium administration really harmful in hospitalized acute kidney injury patients: a propensity score–matched study

Impact of cardiac catheterization timing and contrast media dose on acute kidney injury after cardiac surgery

Differential Incidence of Contrast-Associated Acute Kidney Injury: Comparing Intravenous and Intraarterial Contrast Administration

Incidence of contrast-associated acute kidney injury: a prospective cohort

Safety of ultra‐low contrast coronary angiography in patients with acute kidney injury

Patients with Different Stages of Chronic Kidney Disease Undergoing Intravenous Contrast-Enhanced Computed Tomography—The Incidence of Contrast-Associated Acute Kidney Injury

Prevalence of Contrast-Induced Acute Kidney Injury in Acute Ischemic Stroke Patients Undergoing Contrast-Enhanced CT Angiography at a Tertiary Care Centre

Contrast-associated acute kidney injury in the critically ill: systematic review and Bayesian meta-analysis

The association between nutritional risk and contrast-induced acute kidney injury in patients undergoing coronary angiography: a cross-sectional study

Variation in contrast-associated acute kidney injury prophylaxis for percutaneous coronary intervention: insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking (CART) program

Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury?

Incidence, Risk Factors and Prognosis of Contrast-Induced Acute Kidney Injury in Acute Heart Failure Patients Undergoing Coronary Angiography

Association of Endothelial Cell Activation with Acute Kidney Injury during Coronary Angiography and the Influence of Recombinant Human C1 Inhibitor—A Secondary Analysis of a Randomized, Placebo-Controlled, Double-Blind Trial

Erythrocyte Parameters, Anemia Conditions, and Sex Differences Are Associated with the Incidence of Contrast-Associated Acute Kidney Injury after Coronary Angiography.

Abstract 58: Implementation Of An Electronic Health Records-based Safe Contrast Limit For Preventing Contrast-associated Acute Kidney Injury After Percutaneous Coronary Intervention

Clinical Outcomes of Contrast-Induced Nephropathy in Patients Undergoing Percutaneous Coronary Intervention: A Prospective, Multicenter, Randomized Study to Analyze the Effect of Hydration and Acetylcysteine

Renal Tolerability of Iopromide and Iodixanol in 562 Renally Impaired Patients Undergoing Cardiac Catheterisation: the Direct Study

Association of Red Blood Cell Distribution Width and Hemoglobin-to-rdw Ratio with Contrast-Associated Acute Kidney Injury in Patients Undergoing Coronary Angiography: A Retrospective Study